AcuityMD has raised US$80m to add advanced AI capabilities to its MedTech AI platform and support adoption of medical technology.
The funding brings the company’s total capital raised to more than US$160m and values the business at US$955m.
AcuityMD said MedTech companies face pressure not only to launch innovations successfully, but also to capture and grow market share in an environment shaped by portfolio changes, hospital consolidation, regulatory shifts and reimbursement updates.
Mike Monovoukas, chief executive officer and co-founder of AcuityMD, said the company’s role was to sit between data and the people making decisions.
He said: “AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made.
“AcuityMD is that context layer, serving the rep in the field, the commercial leader planning territories, and the teams launching the next generation of innovation.
“I’m grateful to the hundreds of customers who have helped shape our platform.
“This funding accelerates our shared mission of accelerating adoption of cutting-edge medical technologies.”
The company brings together data from claims databases, FDA filings, government records and market signals into what it describes as a proprietary MedTech ontology, effectively a knowledge map linking physicians, facilities, networks, procedures, reimbursement dynamics and the relationships between them.
That information is then matched with each customer’s internal data, including contracting details, product indications, territory structure and CRM activity, to give a unified and continually updated view of the healthcare market intended to support faster commercial decision-making.
Built on that foundation is AcuityAI, now available in open beta, which the company says combines its ontology with a customer’s business context and each sales representative’s specific situation to surface insights that broader AI platforms cannot replicate.
The new capital will fund three priorities: accelerating agentic AI capabilities for commercial teams including sales reps, leadership and marketing; deepening the MedTech ontology that powers the data model; and expanding the platform beyond commercial use to support the company’s broader mission across the full product lifecycle.
The Series C round was led by existing investor StepStone Group, with additional participation from Benchmark, Redpoint Ventures, ICONIQ and Atreides Management.
Hunter Somerville, partner at StepStone Group, said the company’s data depth was a differentiator.
“AcuityMD is scaling rapidly while continuing to invest thoughtfully in its people and platform,” he said.
“The depth of the company’s data provides a meaningful advantage, and as AI capabilities continue to advance, that foundation becomes more valuable.
“We also see significant opportunities for AcuityMD to benefit the broader MedTech organization beyond commercial, reinforcing our decision to deepen our commitment.”
Gig work apps pushing to deregulate healthcare jobs, report warns
